- Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
- Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
- Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
- Vistagen to Present at Stifel 2024 Virtual CNS Days
- Vistagen to Present at TD Cowen 44th Annual Health Care Conference
- Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
- Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
More ▼
Key statistics
As of last trade, Vistagen Therapeutics Inc (VTGN:NAQ) traded at 4.72, 191.48% above the 52 week low of 1.62 set on Jun 26, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.71 |
---|---|
High | 4.82 |
Low | 4.65 |
Bid | 4.72 |
Offer | 4.74 |
Previous close | 4.70 |
Average volume | 176.89k |
---|---|
Shares outstanding | 27.03m |
Free float | 26.98m |
P/E (TTM) | -- |
Market cap | 127.02m USD |
EPS (TTM) | -3.56 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 19:28 BST.
More ▼